Pointe Capital Management LLC boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 39.3% during the second quarter, Holdings Channel reports. The institutional investor owned 3,866 shares of the medical equipment provider’s stock after buying an additional 1,090 shares during the period. Pointe Capital Management LLC’s holdings in Zimmer Biomet Holdings were worth $496,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Parkside Financial Bank & Trust raised its stake in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after buying an additional 199 shares in the last quarter. IHT Wealth Management LLC raised its stake in shares of Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 256 shares in the last quarter. Sandy Spring Bank raised its stake in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 20 shares in the last quarter. Finally, Ledyard National Bank raised its stake in shares of Zimmer Biomet Holdings by 9.3% in the first quarter. Ledyard National Bank now owns 1,293 shares of the medical equipment provider’s stock worth $157,000 after buying an additional 110 shares in the last quarter. Hedge funds and other institutional investors own 83.62% of the company’s stock.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 110.13 on Friday. The firm has a market capitalization of $22.22 billion, a P/E ratio of 31.37 and a beta of 1.20. The stock’s 50 day moving average price is $125.44 and its 200 day moving average price is $121.28. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The business had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.95 billion. During the same quarter last year, the firm earned $2.02 earnings per share. The firm’s quarterly revenue was up 1.1% compared to the same quarter last year. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.

ILLEGAL ACTIVITY NOTICE: “Pointe Capital Management LLC Purchases 1,090 Shares of Zimmer Biomet Holdings, Inc. (ZBH)” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/11/pointe-capital-management-llc-purchases-1090-shares-of-zimmer-biomet-holdings-inc-zbh.html.

A number of equities research analysts recently commented on the company. Stifel Nicolaus reiterated a “hold” rating and issued a $125.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Needham & Company LLC upped their target price on Zimmer Biomet Holdings from $151.00 to $153.00 and gave the company a “strong-buy” rating in a research report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 target price on Zimmer Biomet Holdings and gave the company a “buy” rating in a research report on Friday, April 28th. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $136.00 target price on shares of Zimmer Biomet Holdings in a research report on Tuesday, July 11th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $137.76.

In related news, insider Sang Yi sold 17,731 shares of Zimmer Biomet Holdings stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Tony W. Collins sold 16,986 shares of Zimmer Biomet Holdings stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. 1.07% of the stock is owned by insiders.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.